|
University
of California, San Francisco
533 Parnassus Avenue, Box 0633
San Francisco, CA 94143-0633
phone:
415-476-0783
fax: 415-502-0888
email: maria.dallera@ucsf.edu
Education:
Dr. Dall’Era graduated from the University of California, Berkeley with a degree in immunology (1993). She then received her M.D. degree (1997) from the University of California, San Francisco. She completed her internal medicine residency (2000) and chief residency (2001) as well as her fellowship training in Rheumatology (2004) at the University of California, San Francisco. She joined the faculty of the University of California, San Francisco in the Division of Rheumatology in 2004. She became Director of the Clinical Trials Center in 2008.
Licensure and Certification:
Board Certification, Internal Medicine and Rheumatology
Medical License, State of California
Research Interests:
Dr. Dall’Era’s primary research interest is the study of novel biologic agents for the treatment of systemic lupus erythematosus (SLE). She is currently involved in several phase I, II, and III clinical trials for both renal and non-renal SLE. She recently completed a phase Ib trial of atacicept (TACI-Ig) in SLE, and is currently participating in the phase II/III trials of atacicept in generalized lupus and lupus nephritis. Dr. Dall’Era and Dr. David Wofsy are the lead investigators on a trial of etanercept for the treatment of lupus nephritis sponsored by the Autoimmune Centers of Excellence. Dr. Dall’Era also directs the UCSF Lupus Clinic in which she follows approximately 300 patients with SLE.
Recent Publications:
Dall’Era, M, Chakravarty, E, Wallace, D, Genovese, M, Kavanaugh, K, Kalunian, K, Dhar, P, Pena-Rossi, C, Wofsy, D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase Ib, double-blind, placebo- controlled, dose escalating trial. Arthritis and Rheumatism. 2007 Dec; 56(12):4142-50.
Gillis, J, Dall’Era, M, Gross A, Davis, J. Six refractory lupus patients treated with rituximab, a case series. Arthritis Care and Research. 2007; 57:538-42.
Dall’Era, M and Wofsy, D. Clinical trial design in systemic lupus erythematosus. Current Opinion in Rheumatology. 2006; 18:476-80.
Dall’Era MC, Cardarelli P, Preston P, Witte A, Davis J. Type I Interferon Correlates with Clinical and Serologic Manifestations of Systemic Lupus Erythematosus. Annals of Rheumatic Disease 2005; 64(12):1692-7.
Dall’Era, M and Davis, J. CTLA4Ig- A Novel Inhibitor of Costimulation. Lupus. 2004; 13(5):372-6.
Dall’Era, M and Davis, J. Systemic Lupus Erythematosus. How to manage, when to refer. Postgraduate Medicine. 2003; 114(5): 31-40. |
